Cancer Treatment Today » lymphoma http://cancertreatmenttoday.org Knowledge is Power Thu, 26 Mar 2026 23:39:25 +0000 en-US hourly 1 Azerra for mantle cell lymphoma http://cancertreatmenttoday.org/azerra-for-mantle-cell-lymphoma/ http://cancertreatmenttoday.org/azerra-for-mantle-cell-lymphoma/#comments Sun, 31 Mar 2013 13:07:40 +0000 M Levin, MD http://cancertreatmenttoday.org/?p=10945 Azerra (ofatumumab) is a new antibiody against Chronic lymphocytic leukemia( CLL).  Preclinical data suggest that it might be more effective than Rituxan in variety of lymphomas.  In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin’s lymphomas. It was approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine and alemtuzumab. In  In early clinical trials, ofatumumab demonstrated single-agent activity against CLL and a number of subtypes of B-cell non-Hodgkin’s lymphomas.

Not much is known about using this drug for mantle cell lymphoma. Preclinical comparisons make it appears superior to rituxumab but there are also studies in which it does not.  A recent review noted that pre-clinical data suggest improved cell killing for ofatumumab compared with rituximab.  Ofatumumab is in a clinical trial for Mantle cell lymphoma:  Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell TransplantThis study is being done to understand how to treat Mantle Cell Lymphoma (MCL).

M. Magni presented an abstract in the 2011 ASH conference. It reported that chemotherapy with bendamustine and ofatumumab appears generally safe and well tolerated to date in MCL patients aged ≥ 65 years requiring treatment. Preliminary data about efficacy are encouraging: accrual is ongoing for further evaluation.

For Professional version see here

]]> http://cancertreatmenttoday.org/azerra-for-mantle-cell-lymphoma/feed/ 0 Zolinza for Hodgkin’s http://cancertreatmenttoday.org/zolinza-for-hodgkins/ http://cancertreatmenttoday.org/zolinza-for-hodgkins/#comments Fri, 01 Mar 2013 21:03:38 +0000 M Levin, MD http://cancertreatmenttoday.org/?p=10805 Current chemotherapy drugs are very effective for Hodgkin’s  lymphomas but patients who relapse after receiving them don;t do as well. This is because the cancers develop resistance to the se drugs. Zolinza is a new drug approved in the USA for the treatment of cutaneous(skin) T-cell lymphoma who have progressive, persistent or recurrent disease  or following two systemic therapies. It may be effective for Hodgkin’s. For Hodgkin’s, a phase II study enrolled twenty-five eligible patients. The overall resposne rate was low, 4% (one partial response), but the drug was well tolerated. A phase I clinical trial treated several types of lymphoma. The best responses were seen in those with Hodgkin and diffuse large B-cell lymphoma (Budde et al). A study of Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma was started at the City of Hope but was terminated.

For Professional version see here

]]> http://cancertreatmenttoday.org/zolinza-for-hodgkins/feed/ 0